These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803 [TBL] [Abstract][Full Text] [Related]
4. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199 [TBL] [Abstract][Full Text] [Related]
5. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Zhang H; Tian M; Li S; Liu J; Tanada S; Endo K Cancer Biother Radiopharm; 2003 Oct; 18(5):719-26. PubMed ID: 14629820 [TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053 [TBL] [Abstract][Full Text] [Related]
7. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Palmedo H; Bender H; Dierke-Dzierzon C; Carl UM; Risse J; Krebs D; Biersack HJ Clin Nucl Med; 1999 Sep; 24(9):643-8. PubMed ID: 10478737 [TBL] [Abstract][Full Text] [Related]
8. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669 [TBL] [Abstract][Full Text] [Related]
9. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cheng A; Chen S; Zhang Y; Yin D; Dong M Cancer Biother Radiopharm; 2011 Apr; 26(2):237-44. PubMed ID: 21539455 [TBL] [Abstract][Full Text] [Related]
10. Rhenium-188-HEDP in the palliative treatment of bone metastases. Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533 [TBL] [Abstract][Full Text] [Related]
11. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023 [TBL] [Abstract][Full Text] [Related]
12. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. Liepe K; Runge R; Kotzerke J J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184 [TBL] [Abstract][Full Text] [Related]
13. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998 [TBL] [Abstract][Full Text] [Related]
15. [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)]. Holle LH; Humke U; Trampert L; Ziegler M; Kirsch CM; Oberhausen E Urologe A; 1997 Nov; 36(6):540-7. PubMed ID: 9487590 [TBL] [Abstract][Full Text] [Related]
16. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825 [TBL] [Abstract][Full Text] [Related]
17. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Sciuto R; Festa A; Pasqualoni R; Semprebene A; Rea S; Bergomi S; Maini CL Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096 [TBL] [Abstract][Full Text] [Related]
19. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. Liepe K; Kropp J; Hliscs R; Franke WG Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588 [TBL] [Abstract][Full Text] [Related]
20. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]